

Arthur Weinstein, FACP, FRCP, MACR

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5864528/publications.pdf>

Version: 2024-02-01

17
papers

1,041
citations

932766

10
h-index

940134

16
g-index

17
all docs

17
docs citations

17
times ranked

866
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review of Complement Activation in SLE. <i>Current Rheumatology Reports</i> , 2021, 23, 16.	2.1	71
2	A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. <i>ACR Open Rheumatology</i> , 2021, 3, 116-123.	0.9	5
3	A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000528.	1.1	5
4	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 78-88.	2.9	33
5	Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP). <i>ACR Open Rheumatology</i> , 2020, 2, 629-639.	0.9	3
6	A Combination of Complement Activation Products With Autoantibodies Predicts Transition of Probable Lupus to Systemic Lupus Erythematosus: Comment on the Article by Lambers et al. <i>Arthritis Care and Research</i> , 2020, 72, 1827-1827.	1.5	0
7	Cell-bound complement activation products associate with lupus severity in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000377.	1.1	7
8	Cell-Bound Complement Activation Products Are Superior to Serum Complement C3 and C4 Levels to Detect Complement Activation in Systemic Lupus Erythematosus: Comment on the Article by Aringer et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 860-860.	2.9	2
9	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1125-1134.	2.9	74
10	Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. <i>Lupus Science and Medicine</i> , 2019, 6, e000349.	1.1	9
11	Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. <i>Journal of Immunological Methods</i> , 2017, 446, 54-59.	0.6	18
12	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , 2014, 1, e000056.	1.1	65
13	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 300-309.	1.0	149
14	Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 4040-4047.	6.7	66
15	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
16	Lyme arthritis and post-Lyme disease syndrome. <i>Current Opinion in Rheumatology</i> , 2002, 14, 383-387.	2.0	47
17	Antibodies to native DMA and serum complement (C3) levels. <i>American Journal of Medicine</i> , 1983, 74, 206-216.	0.6	90